Coverage
-
September 16, 2011
Sun Pharmaceutical Industries Ltd. can't market its generic version of Sanofi-Aventis SA's colorectal cancer treatment Eloxatin until August 2012, based on the terms of a licensing agreement between the companies, a New Jersey federal judge said Thursday.
9 other articles on this case.
View all »